REYVOW Drug Patent Profile
✉ Email this page to a colleague
When do Reyvow patents expire, and what generic alternatives are available?
Reyvow is a drug marketed by Eli Lilly And Co and is included in one NDA. There are four patents protecting this drug and one Paragraph IV challenge.
This drug has one hundred and sixty-eight patent family members in forty-seven countries.
The generic ingredient in REYVOW is lasmiditan succinate. One supplier is listed for this compound. Additional details are available on the lasmiditan succinate profile page.
DrugPatentWatch® Generic Entry Outlook for Reyvow
Reyvow was eligible for patent challenges on January 31, 2024.
By analyzing the patents and regulatory protections it appears that the earliest date
for generic entry will be December 5, 2037. This may change due to patent challenges or generic licensing.
There is one Paragraph IV patent challenge for this drug. This may lead to patent invalidation or a license for generic production.
Indicators of Generic Entry
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for REYVOW?
- What are the global sales for REYVOW?
- What is Average Wholesale Price for REYVOW?
Summary for REYVOW
International Patents: | 168 |
US Patents: | 4 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 84 |
Patent Applications: | 160 |
Drug Prices: | Drug price information for REYVOW |
What excipients (inactive ingredients) are in REYVOW? | REYVOW excipients list |
DailyMed Link: | REYVOW at DailyMed |


DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for REYVOW
Generic Entry Date for REYVOW*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
TABLET;ORAL |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Paragraph IV (Patent) Challenges for REYVOW
Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
---|---|---|---|---|---|---|
REYVOW | Tablets | lasmiditan succinate | 50 mg and 100 mg | 211280 | 1 | 2024-01-31 |
US Patents and Regulatory Information for REYVOW
REYVOW is protected by four US patents and one FDA Regulatory Exclusivity.
Based on analysis by DrugPatentWatch, the earliest date for a generic version of REYVOW is ⤷ Try for Free.
This potential generic entry date is based on patent 11,053,214.
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Eli Lilly And Co | REYVOW | lasmiditan succinate | TABLET;ORAL | 211280-001 | Jan 31, 2020 | RX | Yes | No | 7,423,050 | ⤷ Try for Free | Y | Y | ⤷ Try for Free | ||
Eli Lilly And Co | REYVOW | lasmiditan succinate | TABLET;ORAL | 211280-002 | Jan 31, 2020 | RX | Yes | Yes | 12,257,246 | ⤷ Try for Free | ⤷ Try for Free | ||||
Eli Lilly And Co | REYVOW | lasmiditan succinate | TABLET;ORAL | 211280-001 | Jan 31, 2020 | RX | Yes | No | 12,071,423 | ⤷ Try for Free | Y | ⤷ Try for Free | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for REYVOW
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Eli Lilly And Co | REYVOW | lasmiditan succinate | TABLET;ORAL | 211280-001 | Jan 31, 2020 | 8,748,459 | ⤷ Try for Free |
Eli Lilly And Co | REYVOW | lasmiditan succinate | TABLET;ORAL | 211280-002 | Jan 31, 2020 | 8,748,459 | ⤷ Try for Free |
Eli Lilly And Co | REYVOW | lasmiditan succinate | TABLET;ORAL | 211280-003 | Dec 18, 2020 | 8,748,459 | ⤷ Try for Free |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for REYVOW
When does loss-of-exclusivity occur for REYVOW?
Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:
Australia
Patent: 17373784
Patent: Compositions and methods related to pyridinoylpiperidine 5-HT1F agonists
Estimated Expiration: ⤷ Try for Free
Brazil
Patent: 2019010934
Patent: composições e métodos relacionados a agonistas de piridinoilpiperidina 5-ht1f
Estimated Expiration: ⤷ Try for Free
Canada
Patent: 43772
Patent: HYDRATES DE 2,4,6-TRIFLUORO-N-[6-(1-METHYL-PIPERIDINE-4-CARBONYLE)-PYRIDIN-2-YL]-BENZAMIDE D'HEMISUCCINATE ET UTILISATIONS CONNEXES EN TANT QU'AGONISTE DE 5-HT1F (HYDRATES OF 2,4,6-TRIFLUORO-N-[6-(1-METHYL-PIPERIDINE-4-CARBONYL)-PYRIDIN-2-YL]-BENZAMIDE HEMISUCCINATE, AND USES THEREOF AS A 5-HT1F AGONIST)
Estimated Expiration: ⤷ Try for Free
Chile
Patent: 19001426
Patent: Composiciones y métodos relacionados con agonistas de piridinoilpiperidina 5-ht1f.
Estimated Expiration: ⤷ Try for Free
China
Patent: 0291079
Patent: 与吡啶酰基哌啶5-HT激动剂相关的组合物和方法 (COMPOSITIONS AND METHODS RELATED TO PYRIDINOYLPIPERIDINE 5-HT1F AGONISTS)
Estimated Expiration: ⤷ Try for Free
Patent: 5385893
Patent: 与吡啶酰基哌啶5-HT1F激动剂相关的组合物和方法 (Compositions and methods related to picolinylpiperidine 5-HT1F agonists)
Estimated Expiration: ⤷ Try for Free
Patent: 5385894
Patent: 与吡啶酰基哌啶5-HT1F激动剂相关的组合物和方法 (Compositions and methods related to picolinylpiperidine 5-HT1F agonists)
Estimated Expiration: ⤷ Try for Free
Colombia
Patent: 19005290
Patent: Composiciones y métodos relacionados con agonistas de piridinoilpiperidina 5-ht1f
Estimated Expiration: ⤷ Try for Free
Costa Rica
Patent: 190251
Patent: COMPOSICIONES Y MÉTODOS RELACIONADOS CON AGONISTAS DE PIRIDINOILPIPERIDINA 5-HT 1F (COMPOSITIONS AND METHODS RELATED TO PYRIDINOYLPIPERIDINE 5-HT1F AGONISTS)
Estimated Expiration: ⤷ Try for Free
Croatia
Patent: 0211557
Estimated Expiration: ⤷ Try for Free
Cyprus
Patent: 24540
Estimated Expiration: ⤷ Try for Free
Denmark
Patent: 51617
Estimated Expiration: ⤷ Try for Free
Dominican Republic
Patent: 019000139
Patent: COMPOSICIONES Y MÉTODOS RELACIONADOS CON AGONISTAS DE PIRIDINOILPIPERIDINA 5-HT1F
Estimated Expiration: ⤷ Try for Free
Ecuador
Patent: 19040190
Patent: COMPOSICIONES Y MÉTODOS RELACIONADOS CON AGONISTAS DE PIRIDINOILPIPERIDINA 5-HT1F
Estimated Expiration: ⤷ Try for Free
Eurasian Patent Organization
Patent: 1991112
Patent: КОМПОЗИЦИИ И СПОСОБЫ, СВЯЗАННЫЕ С ПИРИДИНОИЛПИПЕРИДИНОВЫМИ АГОНИСТАМИ 5-HT1F
Estimated Expiration: ⤷ Try for Free
European Patent Office
Patent: 51617
Patent: COMPOSITIONS ET PROCÉDÉS SE RAPPORTANT À DES AGONISTES DE PYRIDINOYLPIPÉRIDINE 5-HT1F (COMPOSITIONS AND METHODS RELATED TO PYRIDINOYLPIPERIDINE 5-HT1F AGONISTS)
Estimated Expiration: ⤷ Try for Free
Hungary
Patent: 56820
Estimated Expiration: ⤷ Try for Free
Israel
Patent: 6598
Patent: תכשירים ושיטות הקשורים לאגוניסטים של פירידינוילפיפרידין 5-ht1f (Compositions and methods related to pyridinoylpiperidine 5-ht1f agonists)
Estimated Expiration: ⤷ Try for Free
Japan
Patent: 61240
Estimated Expiration: ⤷ Try for Free
Patent: 20500936
Patent: ピリジノイルピペリジン5−HT1Fアゴニストに関する組成物および方法
Estimated Expiration: ⤷ Try for Free
Patent: 22000451
Patent: ピリジノイルピペリジン5−HT1Fアゴニストに関する組成物および方法 (COMPOSITIONS AND METHODS RELATED TO PYRIDINOYLPIPERDINE 5-HT1F AGONISTS)
Estimated Expiration: ⤷ Try for Free
Patent: 23123678
Patent: ピリジノイルピペリジン5-HT1Fアゴニストに関する組成物および方法 (COMPOSITIONS AND METHODS RELATED TO PYRIDINOYLPIPERIDINE 5-HT1F AGONISTS)
Estimated Expiration: ⤷ Try for Free
Patent: 24178323
Patent: ピリジノイルピペリジン5-HT1Fアゴニストに関する組成物および方法 (COMPOSITION AND METHOD RELATED TO PYRIDINOYL-PIPERIDINE 5-HT1F AGONIST)
Estimated Expiration: ⤷ Try for Free
Jordan
Patent: 0190129
Patent: تركيبات وطرق تتعلق بمواد مساعدة لـ 5-HT1F من بيريدينويل بيبريدين (COMPOSITIONS AND METHODS RELATED TO PYRIDINOYLPIPERIDINE 5-HT1F AGONISTS)
Estimated Expiration: ⤷ Try for Free
Lithuania
Patent: 51617
Estimated Expiration: ⤷ Try for Free
Malaysia
Patent: 6855
Patent: COMPOSITIONS AND METHODS RELATED TO PYRIDINOYLPIPERIDINE 5-HT1F AGONISTS
Estimated Expiration: ⤷ Try for Free
Mexico
Patent: 19006520
Patent: COMPOSICIONES Y METODOS RELACIONADOS CON AGONISTAS DE PIRIDINOILPIPERIDINA 5-HT1F. (COMPOSITIONS AND METHODS RELATED TO PYRIDINOYLPIPERIDINE 5-HT1F AGONISTS.)
Estimated Expiration: ⤷ Try for Free
Patent: 21014139
Patent: COMPOSICIONES Y MÉTODOS RELACIONADOS CON AGONISTAS DE PIRIDINOILPIPERIDINA 5-HT1F. (COMPOSITIONS AND METHODS RELATED TO PYRIDINOYLPIPERIDINE 5-HT1F AGONISTS.)
Estimated Expiration: ⤷ Try for Free
Moldova, Republic of
Patent: 51617
Estimated Expiration: ⤷ Try for Free
Morocco
Patent: 920
Patent: COMPOSITIONS ET PROCÉDÉS SE RAPPORTANT À DES AGONISTES DE PYRIDINOYLPIPÉRIDINE 5-HT1F
Estimated Expiration: ⤷ Try for Free
New Zealand
Patent: 2906
Patent: Compositions and methods related to pyridinoylpiperidine 5-ht1f agonists
Estimated Expiration: ⤷ Try for Free
Peru
Patent: 191134
Patent: COMPOSICIONES Y METODOS RELACIONADOS CON AGONISTAS DE PIRIDINOILPIPERIDINA 5-HT1F
Estimated Expiration: ⤷ Try for Free
Patent: 241297
Patent: COMPOSICIONES Y METODOS RELACIONADOS CON AGONISTAS DE PIRIDINOILPIPERIDINA 5-HT1F
Estimated Expiration: ⤷ Try for Free
Philippines
Patent: 019501252
Patent: COMPOSITIONS AND METHODS RELATED TO PYRIDINOYLPIPERIDINE 5-HTIF AGONISTS
Estimated Expiration: ⤷ Try for Free
Poland
Patent: 51617
Estimated Expiration: ⤷ Try for Free
Portugal
Patent: 51617
Estimated Expiration: ⤷ Try for Free
Serbia
Patent: 415
Patent: FARMACEUTSKI OBLICI I METODE KOJI SE ODNOSE NA PIRIDINOILPIPERIDIN 5-HT1F AGONISTE (COMPOSITIONS AND METHODS RELATED TO PYRIDINOYLPIPERIDINE 5-HT1F AGONISTS)
Estimated Expiration: ⤷ Try for Free
Slovenia
Patent: 51617
Estimated Expiration: ⤷ Try for Free
South Africa
Patent: 1903449
Patent: COMPOSITIONS AND METHODS RELATED TO PYRIDINOYLPIPERIDINE 5-HT1F AGONISTS
Estimated Expiration: ⤷ Try for Free
South Korea
Patent: 190075130
Patent: 피리디노일피페리딘 5-HT1F 작용제에 관한 조성물 및 방법
Estimated Expiration: ⤷ Try for Free
Patent: 210102497
Patent: 피리디노일피페리딘 5-HT1F 작용제에 관한 조성물 및 방법 (5-HT1F COMPOSITIONS AND METHODS RELATED TO PYRIDINOYLPIPERIDINE 5-HT1F AGONISTS)
Estimated Expiration: ⤷ Try for Free
Patent: 230008257
Patent: 피리디노일피페리딘 5-HT1F 작용제에 관한 조성물 및 방법 (5-HT1F COMPOSITIONS AND METHODS RELATED TO PYRIDINOYLPIPERIDINE 5-HT1F AGONISTS)
Estimated Expiration: ⤷ Try for Free
Spain
Patent: 89476
Estimated Expiration: ⤷ Try for Free
Taiwan
Patent: 71290
Estimated Expiration: ⤷ Try for Free
Patent: 1833097
Patent: Compositions and methods related to pyridinoylpiperidine 5-HT1F agonists
Estimated Expiration: ⤷ Try for Free
Tunisia
Patent: 19000174
Patent: COMPOSITIONS AND METHODS RELATED TO PYRIDINOYLPIPERIDINE 5-HT1F AGONISTS
Estimated Expiration: ⤷ Try for Free
Ukraine
Patent: 4433
Patent: ПІРИДИНОЇЛПІПЕРИДИН, ЙОГО ЗАСТОСУВАННЯ ДЛЯ ЛІКУВАННЯ МІГРЕНІ ТА ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ НА ЙОГО ОСНОВІ (COMPOSITIONS AND METHODS RELATED TO PYRIDINOYLPIPERIDINE 5-HT1F AGONISTS)
Estimated Expiration: ⤷ Try for Free
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
See the table below for additional patents covering REYVOW around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Canada | 3201026 | PROCEDES ET INTERMEDIAIRE POUR LA PREPARATION A GRANDE ECHELLE DE ,4,6,-TRIFLUORO-N-[6-(1-METHYLE-PIPERIDINE-4-CARBONYLE)-PYRIDINE-2-YL]-H EMISUCCINATE DE BENZAMIDE ET LA PREPARATION DE 2,4,6-TRIFLUORO-N-[6-(1-METHYLR-PIPERIDINE-4-CARBONYLE)-PYRIDINE-2-YL]-ACETATE DE BENZAMIDE (PROCESSES AND INTERMEDIATE FOR THE LARGE-SCALE PREPARATION OF 2,4,6-TRIFLUORO-N-[6-(1-METHYL-PIPERIDINE-4-CARBONYL)-PYRIDIN-2-YL]-BENZAMIDE HEMISUCCINATE, AND PREPARATION OF 2,4,6-TRIFLUORO-N-[6-(1-METHYL-PIPERIDINE-4-CARBONYL)-PYRIDIN-2-YL]-BENZAMIDE ACETATE) | ⤷ Try for Free |
Ukraine | 124433 | ПІРИДИНОЇЛПІПЕРИДИН, ЙОГО ЗАСТОСУВАННЯ ДЛЯ ЛІКУВАННЯ МІГРЕНІ ТА ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ НА ЙОГО ОСНОВІ (COMPOSITIONS AND METHODS RELATED TO PYRIDINOYLPIPERIDINE 5-HT1F AGONISTS) | ⤷ Try for Free |
Lithuania | 3551617 | ⤷ Try for Free | |
>Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for REYVOW
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
2413933 | PA2023502,C2413933 | Lithuania | ⤷ Try for Free | PRODUCT NAME: LASMIDITANAS ARBA JO FARMACINIU POZIURIU PRIIMTINA DRUSKA; REGISTRATION NO/DATE: EU/1/21/1587 20220817 |
2413933 | CA 2023 00001 | Denmark | ⤷ Try for Free | PRODUCT NAME: LASMIDITAN ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF; REG. NO/DATE: EU/1/21/1587 20220819 |
2413933 | LUC00295 | Luxembourg | ⤷ Try for Free | PRODUCT NAME: LASMIDITAN ET SES DERIVES PHARMACEUTIQUEMENT ACCEPTABLES (RAYVOW); AUTHORISATION NUMBER AND DATE: EU/1/21/1587 20220819 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Market Dynamics and Financial Trajectory for REYVOW (Lasmiditan)
More… ↓